tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties
PremiumRatingsCellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties
3M ago
Cellectis price target lowered to $4 from $5 at Barclays
Premium
The Fly
Cellectis price target lowered to $4 from $5 at Barclays
3M ago
Cellectis SA Reports Q1 2025 Financial Results
Premium
Company Announcements
Cellectis SA Reports Q1 2025 Financial Results
3M ago
Cellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies
PremiumCompany AnnouncementsCellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies
5M ago
Cellectis Advances Clinical Programs and Strengthens AstraZeneca Partnership
Premium
Company Announcements
Cellectis Advances Clinical Programs and Strengthens AstraZeneca Partnership
5M ago
Cellectis reports Q4 EPS (64c) vs (17c) last year
Premium
The Fly
Cellectis reports Q4 EPS (64c) vs (17c) last year
5M ago
Cellectis reports Q3 EPS (22c), consensus (21c)
PremiumThe FlyCellectis reports Q3 EPS (22c), consensus (21c)
10M ago
CMVLF Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
CMVLF Earnings this Week: How Will it Perform?
10M ago
Cellectis publishes pre-clinical evidence MUC1 CAR T-cells  reducing  certain BC
Premium
The Fly
Cellectis publishes pre-clinical evidence MUC1 CAR T-cells reducing certain BC
12M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100